 This is a phase 3, multicenter, randomized, double-blind,parallel-group,non-inferiority study to evaluate the efficacy and safety of TAK-385 administered orally in daily dosing 40 mg for 24 weeks, compared with leuprorelin injection once4 weeks, 1.88 mg or 3.75 mg subcutaneous SCtime in premenopausal participants 20 years of age with symptomatic uterine fibroids. The primary objective of this study is to evaluate the efficacy of TAK-385 40 mg administered orally once daily for 12 weeks. 